Spero Therapeutics, Inc. financial data

Symbol
SPRO on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275% % -9.1%
Debt-to-equity 119% % 45%
Return On Assets -58% % -2691%
Operating Margin -115% % -11033%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56,339,295 shares 3.3%
Common Stock, Shares, Outstanding 56,311,795 shares 3.7%
Entity Public Float $69,500,000 USD -8.6%
Common Stock, Value, Issued $56,000 USD 3.7%
Weighted Average Number of Shares Outstanding, Basic 56,280,844 shares 4%
Weighted Average Number of Shares Outstanding, Diluted 56,280,844 shares 4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $40,549,000 USD -62%
Revenue from Contract with Customer, Excluding Assessed Tax $64,000 USD -88%
Research and Development Expense $61,711,000 USD -27%
General and Administrative Expense $23,932,000 USD 3.7%
Operating Income (Loss) $46,816,000 USD -4141%
Nonoperating Income (Expense) $3,270,000 USD -31%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $43,836,000 USD -1343%
Earnings Per Share, Basic 0 USD/shares -1088%
Earnings Per Share, Diluted 0 USD/shares -1088%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $48,616,000 USD -36%
Assets, Current $52,323,000 USD -60%
Property, Plant and Equipment, Net $0 USD
Operating Lease, Right-of-Use Asset $1,694,000 USD -50%
Other Assets, Noncurrent $153,000 USD 0%
Assets $54,170,000 USD -60%
Accounts Payable, Current $1,395,000 USD -77%
Employee-related Liabilities, Current $5,643,000 USD 72%
Liabilities, Current $13,649,000 USD -72%
Operating Lease, Liability, Noncurrent $1,452,000 USD -50%
Liabilities $27,676,000 USD -60%
Retained Earnings (Accumulated Deficit) $482,586,000 USD -10%
Stockholders' Equity Attributable to Parent $26,494,000 USD -60%
Liabilities and Equity $54,170,000 USD -60%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,002,000 USD -167%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 56,311,795 shares 3.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,002,000 USD -167%
Deferred Tax Assets, Valuation Allowance $122,257,000 USD 13%
Deferred Tax Assets, Gross $122,257,000 USD 13%
Operating Lease, Liability $4,297,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $4,858,000 USD -26%
Property, Plant and Equipment, Gross $3,620,000 USD 0%
Operating Lease, Liability, Current $1,899,000 USD 9.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,956,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,746,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $561,000 USD -46%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,156,000 USD -34%
Deferred Tax Assets, Operating Loss Carryforwards $42,310,000 USD 65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%